Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, needle-free, pre-filled, single-use auto-injector. It offers Midazolam for epileptic seizure; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster headaches, as well as Hydrocortisone for acute adrenal crisis and Methotrexate for the treatment of rheumatoid arthritis. In addition, the company is developing ZEPIZURE, an emergency treatment for managing epileptic seizures. The company was incorporated in 2001 and is based in Dijon, France.
Frequently asked questions
What sector does CROSSJECT SA EO -10 (74C) operate in?
CROSSJECT SA EO -10 belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.
What is CROSSJECT SA EO -10 (74C) current stock price?
As of the latest data, CROSSJECT SA EO -10 stock price is €1.27, with a previous close of €1.30. CROSSJECT SA EO -10 lost -€0.03 in the last trading session, representing a -2.3% loss.
What is CROSSJECT SA EO -10 (74C) current market capitalization?
CROSSJECT SA EO -10 market cap is approximately 76.78 million.
What is CROSSJECT SA EO -10 (74C) Earnings Per Share (EPS)?
The trailing EPS is -€0.19.
Does CROSSJECT SA EO -10 (74C) pay dividends?
No. CROSSJECT SA EO -10 does not pay a dividend.
What is CROSSJECT SA EO -10 (74C) beta (volatility) score?
CROSSJECT SA EO -10 has a beta of 0.497, indicating lower volatility than the overall market.